Today's journal articles

A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the united states from 2003 to 2005.

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

No clinical trials today

Previous Journal Entries

The CB-1 Receptor Antagonist Rimonabant Modulates the Interaction Between Adipocytes and Pancreatic Beta-Cells in Vitro.

Colesevelam HCl to Treat Hypercholesterolemia and Improve Glycemia in Prediabetes: A Randomized, Prospective Study.

Initial Combination Therapy With Metformin and Colesevelam Safely Achieves Glycemic and Lipid Goals in Early Type 2 Diabetes.

Discovery of 2 - (4 - ((1H - 1,2,4 - triazol - 1 - yl)methyl) - 5 - (4 - bromophenyl) - 1 - (2 - chlorophenyl) - 1H - pyrazol - 3 - yl) - 5 - tert - butyl - 1,3,4 - thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid - 1 receptor antagonist.

The nitric oxide-donating pravastatin, NCX 6550, inhibits cytokine release and NF-kappaB activation while enhancing PPARgamma expression in human monocyte/macrophages.

URINE PROTEOME ANALYSIS MAY ALLOW NON-INVASIVE DIFFERENTIAL DIAGNOSIS OF DIABETIC NEPHROPATHY.

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.

Effects of Add-on Fluvastatin Therapy in Patients with Chronic Proteinuric Nephropathy on Dual Renin-Angiotensin System Blockade: The ESPLANADE Trial.

Human Cord Blood-derived Endothelial Progenitor Cells and their Conditioned Media Exhibit Therapeutic Equivalence for Diabetic Wound Healing.

Nicotinic acetylcholine receptor alpha1 promotes calpain-1 activation and macrophage inflammation in hypercholesterolemic nephropathy.

Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin resistant adolescents: a prospective, placebo-controlled, randomized study.

Characterization of new PPARgamma agonists: Benzimidazole derivatives - importance of positions 5 and 6, and computational studies on the binding mode.

A mutant selective anti - estrogen is a pure antagonist on EREs and AP - 1 response elements.

Effect of Ezetimibe Monotherapy on Lipid Metabolism and Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Type 2 Diabetic Patients.

Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.

Synthesis and cannabinoid - 1 receptor binding affinity of conformationally constrained analogs of taranabant.

1 - Methyl - 1H - pyrrole - 2 - carbonitrile containing tetrahydronaphthalene derivatives as non - steroidal progesterone receptor antagonists.

Regulatory effects of Y4 receptor agonist (BVD-74D) on food intake.

One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice.

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects.

Today's News Items

\"Ovatech™ reports successful completion Phase 2 clinical trial

Bionovo Receives Positive Guidance from FDA on Menerba

Training Courses & Meetings

No events listed

Previous News Items

Bionovo Receives Positive Guidance from FDA on Menerba

---

For faster discovery, automatically organize PubMed results into categories